July 13, 2022
Teva Pharmaceuticals USA, Inc., Petitioner v. GlaxoSmithKline LLC, et al.
Case Number:
22-37
Court:
Nature of Suit:
830 Patent Infringement (Fed. Question)
Firms
Companies
Sectors & Industries:
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
May 15, 2023
High Court Refuses To Hear 'Skinny Label' Drug Patent Case
The U.S. Supreme Court on Monday refused to review a Federal Circuit decision that put a spotlight on so-called skinny labels for generic drugs and resulted in Teva Pharmaceuticals being found liable for $235 million for infringing a GlaxoSmithKline heart drug patent.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login